Bacterial infections are one of the leading causes of illnesses world over. On this front, Strides Arcolab has received the U.S FDA approval for Clindamycin Injection, USP, which is an antibiotic used for the treatment of bacterial attacks.
The aforesaid vaccine is touted to be available in 3 single-dose vial sizes and as bulk packaging in pharmacy. Just like any other medicine in Strides, Sagent JV, Clindamycin utilizes the Prevent IV Measures packaging and labeling that is formulated to decrease the medication errs.
Clindamysin is the twelfth product to receive the FDA approval in the Sagent – Strides partnership. The company is creating and supplying above 25 injectable products for the US stores that will be marketed by Sagent. Agila is the specialties unit of Strides Arcolab.
Clindamycin essentially treats anaerobic infections due to anaerobic bacteria that also includes problems of the respiratory tract, skin, teeth and soft tissue infections. In patients who are very reactive to penicillins, the aforesaid injection can be used to strike aerobic bacteria too. It is also commonly used for bone and joint infections specifically those inflicted by Staphylococcus aureus. Moderate acne also seems to be treatable by topical application of clindamycin phosphate.
As per IMS, the injectable Clindamycin equates to nearly $65 million inclusive of bags in the US market. It will be launched in early 2012.